MRNA-1030 is under clinical development by Moderna and currently in Phase II for Influenzavirus B Infections. According to GlobalData, Phase II drugs for Influenzavirus B Infections have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MRNA-1030’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
mRNA-1030 is under development for the prevention of seasonal influenza, including seasonal influenza A H1N1, H3N2 and influenza B yamagata and victoria. The therapeutic candidate comprises of eight mRNAs targeting both hemagglutinin and neuraminidase antigens. It is administered through intramuscular route. It is an mRNA vaccine being developed based on mRNA expression platform technology.
Moderna is a biotechnology company that focuses on the development of messenger RNA therapeutics and vaccines. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular. Moderna through its mRNA therapeutics platform develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It also develops therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology, and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of MRNA-1030’s drug-specific PTSR and LoA scores, buy the report here.